| 000 | 03063nam a22004695i 4500 | ||
|---|---|---|---|
| 001 | u377251 | ||
| 003 | SIRSI | ||
| 005 | 20160812084453.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 121026s2011 sp | s |||| 0|eng d | ||
| 020 |
_a9788493806279 _9978-84-938062-7-9 |
||
| 040 | _cMX-MeUAM | ||
| 050 | 4 | _aRA427.8 | |
| 082 | 0 | 4 |
_a613 _223 |
| 082 | 0 | 4 |
_a614.44 _223 |
| 100 | 1 |
_aGarcía-Fontes, Walter. _eauthor. |
|
| 245 | 1 | 0 |
_aIncentives for Research, Development, and Innovation in Pharmaceuticals _h[recurso electrónico] / _cby Walter García-Fontes. |
| 264 | 1 |
_aMadrid : _bSpringer Healthcare Iberica : _bImprint: Springer Healthcare, _c2011. |
|
| 300 |
_aIX, 96 p. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 | _aEconomía de la Salud y Gestión Sanitaria | |
| 505 | 0 | _aIntroduction -- Incentives for innovation: a survey -- Incentives for innovation: neglected diseases -- When patents are not enough: supplementary incentives for pharmaceutical innovation -- The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003 -- The use of pay for performance for drugs: can it improve incentives for innovation? -- Drug Price Regulation: Recent Trends and Downstream Neglected Issues. | |
| 520 | _aIncentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement diffe - rent measures that promote research in these less profitable areas. The lack of incentives for innovation is especially dramatic when we take into account diseases affecting mostly low-income countries, and also diseases affecting small groups of patients. How can incentives be provided to deal with these less profitable acti - vities when no clear markets exist for the innovations being introduced? Some of the contributions of this book go into discussing alternative mechanisms to substitute for these inexistent markets, and situations where traditional instruments such as public procurement or direct subsidies have proven totally insufficient. Also, this book discusses the clear mismatch between the size of the markets being targeted and the incentives being provided. | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 |
_aMedical records _xData processing. |
|
| 650 | 1 | 4 | _aMedicine & Public Health. |
| 650 | 2 | 4 | _aHealth Promotion and Disease Prevention. |
| 650 | 2 | 4 | _aHealth Economics. |
| 650 | 2 | 4 | _aHealth Informatics. |
| 650 | 2 | 4 | _aMedicine/Public Health, general. |
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9788493806217 |
| 830 | 0 | _aEconomía de la Salud y Gestión Sanitaria | |
| 856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-84-938062-7-9 |
| 596 | _a19 | ||
| 942 | _cLIBRO_ELEC | ||
| 999 |
_c205131 _d205131 |
||